After graduating from
the Victoria University of Manchester Peter first worked for Boots Pharmaceuticals.
He then moved into technical sales with Orme Scientific, Manchester where he established their external sales office in the South East of
England. Later he established the UK division of the
PCR instrument manufacturer, Biometra Gmbh, Goettingen, Germany. He managed this
operation and then coordinated the subsequent sale of the company into
Whatman plc , Maidstone, UK. The successful
integration of the business into the plc coupled
with other biotech acquisitions during his tenure helped double the share
price of the plc and moved the company away from its paper making roots and firmly
established them in the biotech sector.
He was then approached by the genomics company MWG-Biotech, Munich,
Germany to establish their facility in Milton Keynes, UK.
He grew the business from $zero to $20M in 3 years and
was subsequently invited to join the Main Board in Munich. Some years
later he returned to the UK as one of the founders of the London Technology Network, a joint venture
between London Business School and London universities. One succesful spin off from this was Peter’s next challenge;
the establishment of the first UK Korean genomics company and it's sister DNA production facility
in Alameda, USA.This vast experience
is now being chanelled into his next step as the COO of MP Sciences,
a company that will be the major portal for the latest genomic and proteomic
technologies.Peter is a member of the Royal Pharmaceutical Society
of Great Britain, a board member of Milton Partnerships, a member of the British
Proteomics Society Executive committee, the Institute of Directors and advisor to
several Health Authority Patient advisory groups.